多价菌体纳米乳液增强T4菌体的胃肠道稳定性和保持杀菌活性
Huangliang Zheng1, Xu Huang2, Juan Du3
1School of Pharmacy, The Chinese University of Hong Kong, Shatin, Hong Kong.
Food research international (Ottawa, Ont.)
|January 15, 2026
概括
这项研究开发了纳米乳液,以保护细菌体 (菌体) 免受消化,改善口服输送,用于食品工业中的抗菌应用. 优化的配方显著提高了胃肠道中菌体的存活率和疗效.
科学领域:
- 微生物学 微生物学
- 生物技术是生物技术.
- 食品科学 食品科学 食品科学
背景情况:
- 菌体在整个食品供应链中显示出作为抗菌剂的潜力.
- 口服菌体受阻于胃肠道中的降解.
- 开发稳定的口服菌体配方对于食品工业应用至关重要.
研究的目的:
- 通过创建保护性纳米乳液来增强口腔菌体的输送.
- 为了优化菌素-基托桑结合纳米乳液,以提高胃肠道的稳定性和有效性.
- 在模拟和体内模型中评估配方的性能.
主要方法:
- 合成了T4菌素-基托联体,并将它们与脂一起自组合成纳米乳液.
- 在模拟的胃肠道条件下,评估了基托桑度对移植效率和菌体活力的影响.
- 在肠道表皮细胞模型中对侵入性细菌和生物膜进行评估的抗菌活性.
- 在小鼠模型中测试了优化配方 (Phage-CL-50) 的胃肠道菌体保留和性能.
主要成果:
- 具有中等度奇托桑 (50-100μg/mL) 的纳米乳液提供了最佳的保护,在胃过境期间维持了大约5 log10 PFU/mL的菌体活力.
- 较高度的奇托桑降低了菌体的活力和释放,而较低度导致纳米乳液组装不足.
- 优化的Phage-CL-50配方表现出对肠道细菌和生物膜的卓越疗效,具有可恢复的体运输.
- 在小鼠体内研究显示,Phage-CL-50显著增强了胃肠道菌体保留和抗菌性能.
结论:
- 纳米乳液封装的菌体 - 基托桑结合物提供了一个可行的策略,用于稳健的口服菌体输送.
- 有针对性的配方优化是克服与胃肠道环境中菌体稳定性相关的挑战的关键.
- 这种方法有望为食品工业开发有效的口腔菌体解决方案.
更多相关视频
07:22Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
Published on: August 19, 2021
3.4K
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
2.3K
相关概念视频
01:26DNA Bacteriophages
824
Bacteriophages, or phages, are viruses that specifically infect bacteria, utilizing their genetic material to hijack host cellular machinery for replication. DNA bacteriophages employ single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA) genomes. These phages exhibit diverse replication strategies and host interactions, influencing their ecological roles and applications in biotechnology and medicine.ssDNA BacteriophagesssDNA phages, with their small genomes, utilize unique strategies to...
824
01:30Lytic Cycle of Bacteriophages
77.4K
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...
77.4K
01:20Viral Replication: Lytic Cycle
1.3K
Bacteriophages, or phages, are viruses that specifically infect bacteria. Among them, T-even bacteriophages, such as T4, exhibit a well-characterized lytic replication cycle in Escherichia coli (E. coli). This process ensures the rapid proliferation of the virus while ultimately leading to the destruction of the bacterial host.Attachment and DNA InjectionThe infection process begins with the recognition and binding of the T4 phage to the E. coli cell surface. Tail fibers of the phage...
1.3K
01:16Viral Replication: Lysogenic Cycle
1.4K
The lysogenic cycle is a crucial viral replication strategy that allows bacteriophages to persist within host cells without immediately destroying them. This process is primarily observed in temperate phages, such as bacteriophage lambda (λ), which infects Escherichia coli. The cycle allows the viral genome to persist across bacterial generations while keeping host cells viable.Integration of the Viral GenomeUpon infection, bacteriophage lambda attaches to the bacterial surface and injects...
1.4K
00:43Lysogenic Cycle of Bacteriophages
67.3K
In contrast to the lytic cycle, phages infecting bacteria via the lysogenic cycle do not immediately kill their host cell. Instead, they combine their genome with the host genome, allowing the bacteria to replicate the phage DNA along with the bacterial genome. The incorporated copy of the phage genome is called the prophage. Some prophages can re-activate and enter the lytic cycle. This often occurs in response to a perturbation, such as DNA damage, but can also transpire in the absence of...
67.3K
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
200
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
200